Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The cost of breast cancer screening in the Medicare population.
Gross CP, Long JB, Ross JS, Abu-Khalaf MM, Wang R, Killelea BK, Gold HT, Chagpar AB, Ma X. Gross CP, et al. JAMA Intern Med. 2013 Feb 11;173(3):220-6. doi: 10.1001/jamainternmed.2013.1397. JAMA Intern Med. 2013. PMID: 23303200 Free PMC article.
Impact of financial burden of cancer on survivors' quality of life.
Fenn KM, Evans SB, McCorkle R, DiGiovanna MP, Pusztai L, Sanft T, Hofstatter EW, Killelea BK, Knobf MT, Lannin DR, Abu-Khalaf M, Horowitz NR, Chagpar AB. Fenn KM, et al. J Oncol Pract. 2014 Sep;10(5):332-8. doi: 10.1200/JOP.2013.001322. Epub 2014 May 27. J Oncol Pract. 2014. PMID: 24865220
Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making.
Dzimitrowicz H, Mougalian S, Storms S, Hurd S, Chagpar AB, Killelea BK, Horowitz NR, Lannin DR, Harigopal M, Hofstatter E, DiGiovanna MP, Adelson KB, Silber A, Abu-Khalaf M, Chung G, Zaheer W, Abdelghany O, Hatzis C, Pusztai L, Sanft TB. Dzimitrowicz H, et al. J Oncol Pract. 2017 Dec;13(12):e1012-e1020. doi: 10.1200/JOP.2017.022731. Epub 2017 Oct 19. J Oncol Pract. 2017. PMID: 29048991
Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.
Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Burrello T, Abu-Khalaf M, Sabbath K, Sanft T, Brandt DS, Hofstatter EW, Hatzis C, DiGiovanna MP, Pusztai L. Foldi J, et al. Breast Cancer Res Treat. 2018 Jun;169(2):333-340. doi: 10.1007/s10549-017-4653-2. Epub 2018 Feb 2. Breast Cancer Res Treat. 2018. PMID: 29396664 Clinical Trial.
69 results